Financial Performance - For the three months ended March 31, 2022, research and development expenses increased to $10.7 million, a 10% rise from $9.7 million in the same period of 2021[68] - General and administrative expenses decreased to $4.7 million for the three months ended March 31, 2022, down 11% from $5.2 million in the prior year[72] - The total operating expenses for the three months ended March 31, 2022, were $15.4 million, reflecting a 3% increase compared to $14.9 million for the same period in 2021[68] - The company reported a net cash used in operating activities of $14.1 million for the three months ended March 31, 2022, compared to $13.4 million in the same period of 2021[74] - Net cash used in operating activities for Q1 2022 was $15.4 million, compared to $14.9 million in Q1 2021, with non-cash items totaling $3.1 million in 2022 and $2.9 million in 2021[77] - The company has not generated product revenue or achieved profitability since inception and anticipates continued net losses in the foreseeable future[81] Cash Position - As of March 31, 2022, the company had cash and cash equivalents of $128.1 million and an accumulated deficit of $408.8 million[74] - As of March 31, 2022, the company had approximately $128.1 million in cash and cash equivalents, expected to fund operations through 2023[81] Capital Requirements - The company anticipates needing to raise substantial additional capital to support ongoing operations and growth strategies[63] - Future capital requirements may vary significantly, and the company may need to seek additional funds sooner than planned[81] - Factors influencing future capital requirements include product development costs, regulatory approval expenses, and commercialization activities[83] Clinical Development - The company plans to enroll up to 252 patients in a Phase 1 clinical trial for NL-201, assessing safety and antitumor activity[59] - The company has initiated a clinical collaboration with Merck to evaluate NL-201 in combination with KEYTRUDA®[58] - The company is focused on developing de novo protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity[61] - The company faces potential delays in development programs due to the ongoing COVID-19 pandemic and related economic pressures[83] Investing and Financing Activities - Cash used in investing activities for Q1 2022 primarily consisted of purchases of laboratory equipment, similar to Q1 2021[78] - Net cash provided by financing activities for both Q1 2022 and Q1 2021 was mainly from proceeds from stock option exercises[79] - The company has entered into an ATM Equity Offering Sales Agreement with BofA Securities, allowing for the potential sale of up to $40 million in common stock[75] Accounting and Reporting - There have been no material changes to significant accounting policies during Q1 2022[84] - As a smaller reporting company, the company is not required to provide quantitative and qualitative disclosures about market risk[86]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-K _________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36327 _________________________ Neoleukin Therapeutics, Inc. ( ...

For the transition period from ________ to ________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 Indicate by check mark whether the registr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36327 _____________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36327 ____________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36327 _________________________ Neoleukin Therapeutics, Inc. Washington, D.C. 20549 _________________________ FORM 10-K _________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Registrant's telephone number, including area code): (206) 732-2133 Securities registered pursuant to Section 12(b) of the Act: | Title of each class ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36327 Neoleukin Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0542593 (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Neoleukin Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 98-0542593 (I.R.S. Employer Identification No.) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36327 Neoleukin Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdic ...